LF
NBIX icon

Lansforsakringar Fondforvaltning’s Neurocrine Biosciences NBIX Stock Holding History

Lansforsakringar Fondforvaltning’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.2M Hold
31,888
– – 0.02% 417
2025
Q4 		$4.52M Buy
31,888
+397
+1% +$57.5K 0.02% 427
2025
Q3 		$4.42M Hold
31,491
– – 0.02% 422
2025
Q2 		$3.96M Sell
31,491
-955
-3% -$110K 0.02% 430
2025
Q1 		$3.59M Hold
32,446
– – 0.02% 441
2024
Q4 		$4.43M Buy
+32,446
New +$4.01M 0.02% 420

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lansforsakringar Fondforvaltning's NBIX Position: Q1 2026 in Review

Lansforsakringar Fondforvaltning held its Neurocrine Biosciences (NBIX) position steady in Q1 2026 at 31,888 shares worth $4.2M. The position accounts for 0.02% of the portfolio, ranked #417.

Lansforsakringar Fondforvaltning first reported a position in NBIX in Q4 2024 and has held it in 6 quarters since. The position peaked at $4.52M in Q4 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Lansforsakringar Fondforvaltning held 31,888 shares of Neurocrine Biosciences worth $4.2M as of Q1 2026.
  • Lansforsakringar Fondforvaltning left its Neurocrine Biosciences share count unchanged in Q1 2026.
  • Neurocrine Biosciences made up 0.02% of Lansforsakringar Fondforvaltning's portfolio in Q1 2026, its #417 holding.
  • Lansforsakringar Fondforvaltning first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 6 quarters since.
  • Lansforsakringar Fondforvaltning's Neurocrine Biosciences position peaked at $4.52M in Q4 2025.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Lansforsakringar Fondforvaltning's 13F filing for Q1 2026, filed 23 Apr 2026.